A. Inhibition of homologous recombination repair pathway B. Induction of double-strand DNA breaks C. PARP trapping on DNA strand D. Induction of double-strand DNA breaks and PARP trapping on DNA strand

A. Cisplatin has a 10%–15% response rate in most tumors B. Cisplatin in combination with gemcitabine exhibits synergy in pre-clinical models of triple-negative breast cancer C. PARP inhibitors show single-agent activity in BRCA1/2 mutant ovarian cancer D. PARP inhibitors in combination with temozolomide exhibit activity in glioblastomas

A. Olaparib and bevacizumab combination B. Olaparib maintenance C. Bevacizumab maintenance D. Clinical trial

A. Fatigue is unusual with PARP inhibitor therapy; dose reductions are not commonly recommended for severe fatigue B. Bone marrow suppression is common with PARP inhibitor therapy; weekly CBCs are recommended for the first 2 cycles of therapy for all PARP inhibitors C. Prophylactic antiemetics 30–60 minutes prior to PARP inhibitor dosing may improve patient nausea and/or vomiting commonly associated with PARP inhibitors D. Cardiovascular side effects, such as hypertension, are commonly seen with all PARP inhibitors